Several biotech companies have announced key executive transitions and strategic deals. Danaher appointed Martin Stumpe as CTO and AI officer, while Bill Meury has succeeded Hervé Hoppenot as CEO of Incyte after 11 years. Vor Biopharma pivoted to autoimmune diseases, licensing a Phase 3 fusion protein and raising $175 million. Turnstone Biologics agreed to a buyout by XOMA Royalty Corporation for approximately $8 million, marking an exit from operations. These leadership and strategic shifts reflect evolving company priorities amid competitive industry dynamics.